Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Satellos Bioscience and FSHD Canada Foundation Partner to Fund Phase 2 Trial for Forazapadin in FSHD.
Sep 30, 2026
Contract Type
partnership
TorontoBiotechnology
Description
Satellos Bioscience has partnered with the FSHD Canada Foundation, which committed up to US$5 million in funding for the clinical development of forazapadin targeting facioscapulohumeral muscular dystrophy (FSHD). This collaboration is aimed at advancing treatments in a market lacking approved disease-modifying therapies.
Company Information
Company
Satellos Bioscience
Location
65 FRONT STREET EAST
Toronto, Ontario, Canada
About
Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.
TorontoBiotechnology